BR0009840A - Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes - Google Patents

Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes

Info

Publication number
BR0009840A
BR0009840A BR0009840-0A BR0009840A BR0009840A BR 0009840 A BR0009840 A BR 0009840A BR 0009840 A BR0009840 A BR 0009840A BR 0009840 A BR0009840 A BR 0009840A
Authority
BR
Brazil
Prior art keywords
combination
hcv
ribavirin
antioxidants
combination therapy
Prior art date
Application number
BR0009840-0A
Other languages
English (en)
Inventor
Clifford A Brass
Paul W Glue
Edward Piken
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0009840A publication Critical patent/BR0009840A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "TERAPIA DE COMBINAçãO PARA HCV, CONTENDO RIBAVIRINA EM ASSOCIAçãO COM ANTIOXIDANTES". São descritos processos para o tratamento de pacientes que possuem infecções virais, especialmente infecção crónica de hepatite C pela administração ao dito paciente de uma quantidade terapeuticamente eficiente de uma terapia de combinação de interferon-alfa e ribavirina durante um tempo suficiente para diminuir o RNA de HCV em associação com uma quantidade terapeuticamente eficiente de um antioxidante durante um tempo suficiente para melhorar a hemólise relacionada com a ribavirina.
BR0009840-0A 1999-04-19 2000-04-18 Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes BR0009840A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29468799A 1999-04-19 1999-04-19
PCT/US2000/010240 WO2000062799A1 (en) 1999-04-19 2000-04-18 Hcv combination therapy, containing ribavirin in association with antioxidants

Publications (1)

Publication Number Publication Date
BR0009840A true BR0009840A (pt) 2002-01-08

Family

ID=23134504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009840-0A BR0009840A (pt) 1999-04-19 2000-04-18 Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes

Country Status (14)

Country Link
EP (1) EP1046399A1 (pt)
JP (1) JP2002542202A (pt)
CN (1) CN1355708A (pt)
AR (1) AR023541A1 (pt)
AU (1) AU4463300A (pt)
BR (1) BR0009840A (pt)
CA (1) CA2306039A1 (pt)
CO (1) CO5241354A1 (pt)
HU (1) HUP0200942A3 (pt)
MX (1) MXPA00003974A (pt)
NO (1) NO20015059L (pt)
PE (1) PE20010284A1 (pt)
WO (1) WO2000062799A1 (pt)
ZA (1) ZA200108571B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
JP2003523978A (ja) 2000-02-18 2003-08-12 シャイアー・バイオケム・インコーポレイテッド ヌクレオシドアナログを用いるｆｌａｖｉｖｉｒｕｓ感染の処置もしくは予防するための方法
US20020197235A1 (en) * 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
TWI274585B (en) * 2002-06-03 2007-03-01 Nat Health Research Institutes Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus
EP1567172A2 (en) * 2002-11-29 2005-08-31 GPC Biotech AG Formulations useful against hepatitis c virus infections
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2516333C (en) * 2003-02-21 2011-08-23 Mochida Pharmaceutical Co., Ltd. Drug for reducing side effects in ribavirin / interferon combination therapy
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection

Also Published As

Publication number Publication date
AU4463300A (en) 2000-11-02
ZA200108571B (en) 2003-01-20
CN1355708A (zh) 2002-06-26
NO20015059D0 (no) 2001-10-18
CA2306039A1 (en) 2000-10-19
WO2000062799A1 (en) 2000-10-26
HUP0200942A3 (en) 2003-03-28
HUP0200942A2 (hu) 2002-07-29
MXPA00003974A (es) 2002-03-08
PE20010284A1 (es) 2001-03-05
JP2002542202A (ja) 2002-12-10
NO20015059L (no) 2001-12-19
AR023541A1 (es) 2002-09-04
CO5241354A1 (es) 2003-01-31
EP1046399A1 (en) 2000-10-25

Similar Documents

Publication Publication Date Title
BR0009840A (pt) Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
NZ507621A (en) HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
MY117781A (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
RU2010153688A (ru) Режим дозирования телапревира
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR0016163A (pt) Tratamento de infecções virais que usa levovirin(r)
BR0108997A (pt) Terapia imune adjuvante para hiv
EA200501569A1 (ru) Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
TH46769A (th) การรักษาร่วมของ hcv
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
DK1150981T3 (da) Terapeutisk necleosidforbindelse
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon
ECSP003446A (es) Terapia de combinacion para vhc
TH33755A (th) การรักษาร่วมเพื่อขจัด hcv-rna ที่ตรวจหาได้ในผู้ป่วยที่ติดเชื้อตับอักเสบ c เรื้อรัง

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.